Financial Statements and


(d) Exhibits

 








Exhibit


No.


  


Description






10.1


  


Transition Agreement, dated March 31, 2021, by and between Allena Pharmaceuticals, Inc. and Edward Wholihan







SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

 












Date: April 2, 2021


 



 





 



 


Allena Pharmaceuticals, Inc.









 



 


By:


 


/s/ Richard Katz




 



 



 


Richard Katz




 



 



 


Chief Financial Officer





makes a similar move, sign up!

Other recent filings from the company include the following:

Statement of acquisition of beneficial ownership by individuals - Jan. 25, 2022
Allena Pharmaceuticals Provides Clinical And Corporate Update ALLN-346, - Jan. 4, 2022

Auto Refresh

Feedback